Biochemical and pharmacological aspects of Parkinsonism.
D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002490:Central Nervous System / Q000378:metabolism; D002628:Chemoreceptor Cells; D002746:Chlorpromazine / Q000494:pharmacology; D003342:Corpus Striatum; D003864:Depression, Chemical; D004295:Dihydroxyphenylalanine / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D010302:Parkinson Disease, Secondary / Q000378:metabolism; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D013268:Stimulation, Chemical; D009435:Synaptic Transmission / Q000187:drug effects*
D012701:Serotonin; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine